SJELIOT protocol_summary for open access.pdf (317.7 kB)
Download file

SJ Eliot: PHASE 1 EVALUATION OF LY2606368, A MOLECULARLY-TARGETED CHK1/2 INHIBITOR THERAPY, IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT GROUP 3/GROUP 4 OR SHH MEDULLOBLASTOMA BRAIN TUMORS

Download (317.7 kB)
report
posted on 15.12.2021, 23:08 by Nick G. Gottardo, Janelle JonesJanelle Jones

SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease. Additionally, a small expansion cohort will be incorporated into the trial at the combination MTD/RP2D (maximum tolerated dose/recommended phase two dose) to detect a preliminary efficacy signal.

Funding

Medical Research Future Fund (MRFF)Frontier Health & Medical Research Fund

Department of Health

Find out more...

History

Usage metrics

Exports